
Hemab Therapeutics Raises $157 Million to Advance Bleeding Disorder Treatments
Hemab Therapeutics, a biotechnology company in the clinical stage that focuses on creating new preventative treatments for rare and overlooked bleeding and blood clotting disorders,










